RCUSArcus Biosciences Inc
$28.27
$0.20
(0.71%)
EarningsAug 5
Mkt Cap$3.53B
Vol311,532.00
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run
Key PointsThe president of Arcus Biosciences sold 68,569 shares for $2.0 million during the July 9 and July 10 trading sessions...
Nasdaq News: Markets
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Companys Board of...
Business Wire
New Research Published in Nature Links Clinical Activity with HIF2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a publication in Nature describing new research from the...
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Companys Board of...
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Companys Board of...
Business Wire
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.
Zacks
Arcus Biosciences In Clinical Trial Collaboration With Bristol Myers Squibb For Renal Cell Carcinoma
(RTTNews) - Biopharmaceutical company Arcus Biosciences, Inc. (RCUS) announced Wednesday a clinical trial collaboration and supply agreement with Bristol Myers Squibb (BMY...
Nasdaq News: Markets
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PDL1/VEGFA Bispecific Immunomodulator to Treat Kidney Cancer
Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with...
Business Wire
Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in a fireside chat at the...
Business Wire
Arcus Biosciences (NYSE:RCUS) Issues Earnings Results
Arcus Biosciences (NYSE:RCUS - Get Free Report) posted its earnings results on Tuesday. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.10). Arcus...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest RCUS News
ViewAn Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run
Nasdaq News: Markets
Arcus Biosciences Announces New Employment Inducement Grants
Business Wire
New Research Published in Nature Links Clinical Activity with HIF2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
Business Wire
Advertisement|Remove ads.